Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised
3 days ago
- #weight loss
- #obesity management
- #MASLD
- Weight loss is associated with histological improvement in Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with obesity.
- Tirzepatide, semaglutide, sleeve gastrectomy, and Roux-en-Y gastric bypass were superior to placebo or standard care for achieving MASH resolution.
- Greater total body weight loss (TBWL%) was associated with higher rates of MASH resolution and fibrosis improvement.
- The study highlights the need for adequately powered head-to-head trials due to limited evidence and sparse network structure.
- The findings are exploratory and hypothesis-generating, emphasizing the importance of further research.